930. Deputy George Lawlor asked the Minister for Health if she will intervene to ensure that the belzutafan which was approved by the European Medicines Agency in December 2024 for treatment of the genetic condition Von Hippel Lindau (VHL) is made available to patients in this country; the number of persons with this condition who could benefit from this new treatment; and if she will make a statement on the matter. [45294/26]

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.